Post by
prophetoffactz on Dec 20, 2024 5:08pm
Share price:
MBX's stock is up:
+73% in the last five year.
+5.26% in the last 12 months.
Fiscal revenues from 2020 to fiscal 2024 are up 141.9%.
The lost DCM revenue has been lapped and the company appears to have compelling line-of-sight for another strong year of profitable revenue growth. Kinlytic also has a credible path forward. The company is on an enviable trajectory for building value long term value and the market's confidence will increase with each year of performance going forward. The company has been turned around, has line-of-sight on profitable growth, is and is credibly and diversified path with a winning team. Bloom Burton has increased its price target to $.90. The stock is clarly undervalued. We've also made it through the interest rate shock that has harmed the sector.
This is not when you sell the company as we also have Kinlytic now on a credible path.